Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,000.00 Price Target at Oppenheimer
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price reduced by Oppenheimer from $1,150.00 to $1,000.00 in a report released on Wednesday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. REGN has been the subject of a number of other research reports. StockNews.com cut Regeneron Pharmaceuticals from a […]
7 Nov 07:51 · The Cerbat Gem